Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticlePsoriatic Arthritis

Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS

Meghna Jani, Hector Chinoy and Anne Barton for OUTPASS
The Journal of Rheumatology August 2020, 47 (8) 1204-1208; DOI: https://doi.org/10.3899/jrheum.190253
Meghna Jani
From the Centre for Epidemiology Versus Arthritis, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre; National Institute of Health Research (NIHR), Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, and Manchester University Foundation Trust, Manchester, UK.
M. Jani, MSc, MRCP, PhD, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; H. Chinoy, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; A. Barton, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester University Foundation Trust, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector Chinoy
From the Centre for Epidemiology Versus Arthritis, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre; National Institute of Health Research (NIHR), Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, and Manchester University Foundation Trust, Manchester, UK.
M. Jani, MSc, MRCP, PhD, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; H. Chinoy, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; A. Barton, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester University Foundation Trust, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Barton
From the Centre for Epidemiology Versus Arthritis, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre; National Institute of Health Research (NIHR), Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, and Manchester University Foundation Trust, Manchester, UK.
M. Jani, MSc, MRCP, PhD, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; H. Chinoy, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal Foundation Trust; A. Barton, MSc, FRCP, PhD, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester University Foundation Trust, and Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anne.barton@manchester.ac.uk
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To identify (1) whether tumor necrosis factor inhibitor (TNFi) drug levels/anti-drug antibodies (ADAb) are associated with treatment response and disability in patients with psoriatic arthritis (PsA); and (2) the factors associated with TNFi drug levels.

Methods. Patients were recruited from a national multicenter prospective cohort with longitudinal serum samples and 28-joint count Disease Activity Scores (DAS28)/Health Assessment Questionnaire (HAQ) measurement over 12 months.

Results. Adalimumab (ADA) drug levels were significantly associated with ΔDAS28 (β 0.055, 95% CI 0.011–0.099; p = 0.014) and inversely with HAQ over 12 months (β −0.022, 95% CI −0.043 to −0.00063). Factors significantly associated with ADA drug levels were ADAb levels and body mass index.

Conclusion. Drug level testing in ADA-initiated PsA patients may be useful in determining treatment response/disability over 12 months.

Key Indexing Terms:
  • IMMUNOGENICITY
  • DRUG LEVELS
  • TREATMENT RESPONSE
  • TUMOR NECROSIS FACTOR-α INHIBITORS
  • ANTI-DRUG ANTIBODIES

Footnotes

  • M.J. is supported by an NIHR clinical lectureship and was a Medical Research Council (MRC) Clinical Training Fellow supported by the North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics, during which OUTPASS was established, which is funded by the MRC (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation Unit. This research was funded directly from a small grant from the NIHR Manchester Biomedical Research Unit (now NIHR BRC) to M.J. and was supported by Versus Arthritis (grant references 20380 and 20385). This report includes independent research funded by the NIHR BRC Funding Scheme. The views expressed in this publication are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health.

  • Accepted for publication July 8, 2019.
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS
Meghna Jani, Hector Chinoy, Anne Barton
The Journal of Rheumatology Aug 2020, 47 (8) 1204-1208; DOI: 10.3899/jrheum.190253

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS
Meghna Jani, Hector Chinoy, Anne Barton
The Journal of Rheumatology Aug 2020, 47 (8) 1204-1208; DOI: 10.3899/jrheum.190253
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • APPENDIX 1.
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

IMMUNOGENICITY
DRUG LEVELS
TREATMENT RESPONSE
TUMOR NECROSIS FACTOR-α INHIBITORS
ANTI-DRUG ANTIBODIES

Related Articles

Cited By...

More in this TOC Section

  • Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis
  • Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases
  • Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis
Show more Psoriatic Arthritis

Similar Articles

Keywords

  • IMMUNOGENICITY
  • DRUG LEVELS
  • TREATMENT RESPONSE
  • TUMOR NECROSIS FACTOR-α INHIBITORS
  • ANTI-DRUG ANTIBODIES

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire